Skip to main content
Erschienen in: PharmacoEconomics 11/2005

01.11.2005 | Original Research Article

Eliciting social preference weights for Functional Assessment of Cancer Therapy-Lung health states

verfasst von: Paul Kind, Susan Macran

Erschienen in: PharmacoEconomics | Ausgabe 11/2005

Einloggen, um Zugang zu erhalten

Abstract

Background: The Functional Assessment of Cancer Therapy-Lung (FACT-L) is a multidimensional measure of quality of life developed for use in the evaluation of interventions in lung cancer.
Objective: To develop a set of utility weights that could be used to convert FACT-L into a single index capable of being used in the economic analysis of clinical trial data.
Method: A core set of FACT-L items were valued in two versions of a 14-page postal survey of over 400 members of the UK general population. Respondents valued hypothetical FACT-L health states using a scale from 0 to 100 (worst to best health state). Respondents also valued their own health using the standard form of the EuroQol EQ-5D. Data were entered into an ordinary least squares regression model.
Results: Item weights estimated in regression analysis yielded values for 10 items from the FACT-L. The summary index based on this selected set of FACT-L items has a maximum value of 0.703 and a minimum value of 0.111.
Conclusion: This study demonstrates a practical method of converting a standard condition-specific measure into a form that has the requisite properties to legitimise its use in cost-utility analysis. The methodology used here is not unique to FACT-L and might be considered appropriate for use in converting similar instruments.
Literatur
1.
Zurück zum Zitat Feeny D, Furlong B, Boyle M, et al. Multi-attribute health status classification systems: health utilities index. Pharmacoeconomics 1995; 7 (6: 490–502PubMedCrossRef Feeny D, Furlong B, Boyle M, et al. Multi-attribute health status classification systems: health utilities index. Pharmacoeconomics 1995; 7 (6: 490–502PubMedCrossRef
3.
Zurück zum Zitat Bagust A, Barraza-Llorens M, Philips Z. Deriving a compound quality of life measure from the EORTC-QLQ-C30/LC13 instrument for use in economic evaluations of lung cancer clinical trials. Fur J Cancer 2001; 37 (9): 1081–8 Bagust A, Barraza-Llorens M, Philips Z. Deriving a compound quality of life measure from the EORTC-QLQ-C30/LC13 instrument for use in economic evaluations of lung cancer clinical trials. Fur J Cancer 2001; 37 (9): 1081–8
4.
Zurück zum Zitat Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment Cancer Therapy Scale: development and validation of the measure. J Clin Oncol 1993; 11: 570–9PubMed Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment Cancer Therapy Scale: development and validation of the measure. J Clin Oncol 1993; 11: 570–9PubMed
5.
Zurück zum Zitat Gold MR, Siegel JE, Russell LB et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996 Gold MR, Siegel JE, Russell LB et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
7.
Zurück zum Zitat Lamers LM, Buijt I, Uyl-de Groot C. The development of utility weights for functional assessment of cancer therapy-lung scale (FACT-L) health states [abstract 1366]. 10th annual conference of the International Society for Quality of Life Research (ISOQOL); 2003 Nov 12-15; Prague Lamers LM, Buijt I, Uyl-de Groot C. The development of utility weights for functional assessment of cancer therapy-lung scale (FACT-L) health states [abstract 1366]. 10th annual conference of the International Society for Quality of Life Research (ISOQOL); 2003 Nov 12-15; Prague
8.
Zurück zum Zitat Office for National Statistics. 2001 census: key statistics. London: HMSO, 2002 Office for National Statistics. 2001 census: key statistics. London: HMSO, 2002
9.
Zurück zum Zitat Office for National Statistics. Labour force survey. London: HMSO, 2003 Office for National Statistics. Labour force survey. London: HMSO, 2003
10.
Zurück zum Zitat Evens B, Primatesta P. Health survey for England. London: HMSO, 1996 Evens B, Primatesta P. Health survey for England. London: HMSO, 1996
11.
Zurück zum Zitat Macran S, Kind P. “Death” and the valuation of health-related quality of life. Med Care 2001 Mar; 39 (3): 217–22PubMedCrossRef Macran S, Kind P. “Death” and the valuation of health-related quality of life. Med Care 2001 Mar; 39 (3): 217–22PubMedCrossRef
12.
Zurück zum Zitat Trippoli S, Vaiani M, Lucioni C, et al. Quality of life and utility in patients with non-small cell lung cancer: Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics 2001; 19 (8): 855–63PubMedCrossRef Trippoli S, Vaiani M, Lucioni C, et al. Quality of life and utility in patients with non-small cell lung cancer: Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics 2001; 19 (8): 855–63PubMedCrossRef
13.
Zurück zum Zitat Ko CY, Maggard M, Livingston EH. Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment. J Surg Res 2003; 114 (1): 1–5PubMedCrossRef Ko CY, Maggard M, Livingston EH. Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment. J Surg Res 2003; 114 (1): 1–5PubMedCrossRef
14.
Zurück zum Zitat Griffiths TL, Phillips CJ, Davies S, et al. Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation pro-gramme. Thorax 2001 Oct; 56 (10): 779–84PubMedCrossRef Griffiths TL, Phillips CJ, Davies S, et al. Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation pro-gramme. Thorax 2001 Oct; 56 (10): 779–84PubMedCrossRef
15.
Zurück zum Zitat Czoski-Murray C, Warren E, Chilcott J, et al. The clinical and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess 2004; 8 (13): 1–91 Czoski-Murray C, Warren E, Chilcott J, et al. The clinical and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess 2004; 8 (13): 1–91
Metadaten
Titel
Eliciting social preference weights for Functional Assessment of Cancer Therapy-Lung health states
verfasst von
Paul Kind
Susan Macran
Publikationsdatum
01.11.2005
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 11/2005
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200523110-00006

Weitere Artikel der Ausgabe 11/2005

PharmacoEconomics 11/2005 Zur Ausgabe